GO Main Menu Go Main Contents Go Bottom Menu
  • Yuflyma® is a low volume/high concentration biosimilar of adalimumab available in 40 and 80mg strengths in both Auto injector and pre-filled syringe formats. It was approved by Health Canada on December 24, 2021.

    Yuflyma® image..
    • Product Name : Yuflyma®
    • INN : Adalimumab
    • Indications : Rheumatoid arthritis
      Psoriatic arthritis
      Ankylosing spondylitis
      Psoriasis
      Adult Crohn’s disease
      Adult ulcerative colitis
      Polyarticular juvenile idiopathic arthritis
      Adult and adolescent hidradenitis suppurativa
      Adult and pediatric uveitis
    • Protein Type : Monoclonal antibody (mAb)
    • Strength : 40mg/0.4mL, 80mg/0.8mL
    • Drug Approval Status :Health Canada approved

    This product description is for medical and educational purposes only. They are not intended to promote PR or sales campaigns. For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Vegzelma™ is a biosimilar of bevacizumab developed by Celltrion. It was approved by Health Canada on January 3rd, 2023.

    Vegzelma® image..
    • Product Name : Vegzelma™
    • INN : bevacizumab
    • Indications : Metastatic Colorectal Cancer (mCRC)
      Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
      Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
      Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
      Malignant Glioma (WHO Grade IV) – Glioblastoma
    • Protein Type : Monoclonal antibody (mAb)
    • Strength : 100mg/4mL, 400mg/16mL
    • Drug Approval Status :Health Canada approved

    This product description is for medical and educational purposes only. They are not intended to promote PR or sales campaigns. For more details, please consult a doctor or a medical specialist.

  • Remsima™ SC is the world's first subcutaneous formulation of biosimilar infliximab developed by Celltrion. It was approved by Health Canada for rheumatoid arthritis on January 28, 2021, and for Crohn’s disease and ulcerative colitis on February 15, 2024.

    Remsima™ SC image..
    • Product Name : Remsima™ SC
    • INN : Infliximab
    • Indications : rheumatoid arthritis, Crohn’s disease, ulcerative colitis
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Health Canada approved

    This product description is for medical and educational purposes only. They are not intended to promote PR or sales campaigns. For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

Cookie technology helps us bring you the best possible experience when you visit this website. If you continue without changing your settings, you are agreeing to the cookies on this website. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.